TABLE A2.
Serious Adverse Events During Cycle A
| Serious Adverse Event | THC:CBD (n = 73), No. (%) | Placebo (n = 74), No. (%) |
|---|---|---|
| Neutrophil count decreased | ||
| Vomiting | 1 | 2 |
| Febrile neutropenia | 1 | |
| Fever | ||
| Anemia | 1 | |
| Atrial flutter | ||
| Urinary tract infection | 1 | |
| Cystitis, noninfective | 1 | |
| Cerebral edema | ||
| Dehydration | ||
| Postchemotherapy reaction | ||
| Lymph gland infection | 1 | |
| Anal pain | ||
| Hypokalemia | 1 | |
| Diarrhea | 1 | |
| Abdominal pain | ||
| No. of patients experiencing any SAE | 4 (5%) | 6 (8%) |
Abbreviations: CBD, cannabidiol; SAE, serious adverse event; THC, tetrahydrocannabinol.